(UroToday.com) While there has been a rapid proliferation of treatment options for patients with advanced renal cell carcinoma, these studies have focused on patients with clear cell histology. In contrast, there is a relative dearth of data for the treatment of advanced non-clear cell RCC. Therefore, patients with these tumors may receive agents on the basis of their activity in ccRCC. However, VEGF-receptor inhibitors have been shown to have relatively low activity in patients with papillary RCC (pRCC). However, MET signaling is a key molecular driver in pRCC. Given that there is no optimal therapy for metastatic pRCC, in a plenary abstract presentation in the Oral Abstract Session: Renal Cell Cancer session at the 2021 ASCO GU Cancers Symposium, Dr. Sumanta Pal and colleagues provide results of the SWOG 1500 study examining an existing standard (sunitinib) to putative MET kinase inhibitors in patients with pRCC. Notably, this study was concurrently published in The Lancet.1

X